Literature DB >> 20682566

Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.

C M Tobin1, A M Lovering, E Sweeney, A P MacGowan.   

Abstract

Objectives An analysis of the trough serum concentrations sent to the UK Antimicrobial Reference Laboratory for teicoplanin therapeutic drug monitoring (TDM). Methods All trough concentrations over a 13 year period were analysed and the percentages were calculated for the following: <10 mg/L (a sub-optimal concentration for all); ≥10-<20 mg/L (the target used for ordinary Gram-positive infections); ≥20-<60 mg/L (the target for all severe staphylococcal infections including endocarditis); and ≥60 mg/L (the concentration associated with toxicity). Results The percentage of patients with concentrations of <10 mg/L decreased each year to 13% in 2006. Almost 40% of the samples each year were in the ≥10-<20 mg/L range. In 1996, the percentage of samples in the ≥20-<60 mg/L range reached a study high of ∼70%. That percentage then fell to 30% and increased slowly to 50% at the end of the study. Fewer than 5% of the samples were ≥60 mg/L. Conclusions Our study shows that there is a need to increase the initial dose or extend the number of days that the loading dose is used in a significant number of patients. With such a wide optimal range and a low potential for toxicity, it is unclear why optimal therapy is not achieved in a higher percentage of patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682566     DOI: 10.1093/jac/dkq266

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.

Authors:  Takehito Yamamoto; Nobuhiro Yasuno; Shoichi Katada; Akihiro Hisaka; Norio Hanafusa; Eisei Noiri; Naoki Yahagi; Toshiro Fujita; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

2.  Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Tohru Takata; Keiichi Irie; Kazunori Sano; Osamu Imakyure; Kenichi Mishima; Koujiro Futagami
Journal:  Int J Clin Pharm       Date:  2016-04-28

3.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

Authors:  T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-09       Impact factor: 3.267

4.  Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.

Authors:  Si-Ho Kim; Cheol-In Kang; Kyungmin Huh; Sun Young Cho; Doo Ryeon Chung; Soo-Youn Lee; Yae-Jean Kim; Kyong Ran Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

5.  Therapeutic drug concentrations of teicoplanin in clinical settings.

Authors:  So-Yun Nah; Jae Hyoung Im; Jin Yeob Yeo; Ji-Hyeon Baek; Cheol-Woo Kim; Moon-Seok Nam; Hye-Kyung Lee; Moon-Hyun Chung; Jin-Soo Lee
Journal:  Infect Chemother       Date:  2014-03-21

6.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

7.  Effects of teicoplanin on cell number of cultured cell lines.

Authors:  Tahere Kashkolinejad-Koohi; Iraj Saadat; Mostafa Saadat
Journal:  Interdiscip Toxicol       Date:  2015-03

8.  Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions.

Authors:  Liuliu Gao; Hua Xu; Qi Ye; Sichan Li; Jun Wang; Yan Mei; Changhe Niu; Ting Kang; Chen Chen; Yang Wang
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

9.  Prophylactic antibiotics in elective hip and knee arthroplasty: an analysis of organisms reported to cause infections and National survey of clinical practice.

Authors:  C J Hickson; D Metcalfe; S Elgohari; T Oswald; J P Masters; M Rymaszewska; M R Reed; A P Sprowson
Journal:  Bone Joint Res       Date:  2015-11       Impact factor: 5.853

10.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.